Benitec Biopharma

BNTC · NASDAQ

$9.04+$0.68 (+8.13%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.36

BNTC analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $24.82 (+174.6% upside)

Low: $17.17
Now: $9.04
High: $33.60

Upgrades and downgrades

The latest rating actions, newest first

BNTC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Sep 15, 2026	Maintains	Outperform	$16.00 → $17.00	40%
Wedbush	Jul 28, 2026	Initiates	Outperform	$16.00	40%
Evercore ISI Group	May 12, 2026	Initiates	Outperform	$25.00	51%
HC Wainwright & Co.	Mar 9, 2026	Maintains	Buy	$32.00	43%
HC Wainwright & Co.	Nov 24, 2025	Maintains	Buy	$35.00 → $32.00	43%
HC Wainwright & Co.	Nov 4, 2025	Maintains	Buy	$28.00 → $35.00	43%
Citizens	Nov 4, 2025	Maintains	Market Outperform	$20.00 → $22.00	47%

The case for and against

Updated Apr 17, 2026

Bull case

Benitec Biopharma Inc. shows a promising outlook primarily due to its innovative approach in developing BB-301, a therapeutic for Oculopharyngeal Muscular Dystrophy, with interim clinical results indicating a 100% responder rate and the potential for long-term improvement in patient outcomes. The recent data suggests increased interactions with regulators that could lead to accelerated market entry, alongside favorable pricing opportunities reflecting the treatment's value thanks to demonstrated efficacy. Additionally, Benitec's robust financial position, with $94.5 million in cash and cash equivalents, positions the company well to support the ongoing development and potential regulatory pathways for BB-301.

Bear case

Benitec Biopharma reported a net loss of $0.21 per share for the first quarter of fiscal 2026, a smaller loss than anticipated, primarily attributed to a higher-than-expected number of shares outstanding. The company faces significant risks, including the potential for slower-than-expected clinical trial progress for its BB-301 treatment, negative trial data, and challenges in establishing a regulatory approval pathway. Additionally, there are concerns regarding slow market adoption and long-term dilution risks, which contribute to a cautious financial outlook for the company.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.